GeneGo Extends Agreement with Merck & Co.
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
GeneGo, Inc. has announced that Merck & Co., Inc. has extended its global enterprise agreement. This agreement provides Merck with access to GeneGo's content through MetaBase which includes access to MetaCore and MetaDrug content and GeneGo's internal database of disease biomarkers.
"Effective use of powerful systems biology data mining & analysis solutions have become an essential component of modern day drug discovery and development," said Julie Bryant, VP business development.
"Merck is one of our first customers and we are pleased that they have chosen to renew and extend their agreement."
